Vitatex at ASCO 2017
June 02, 2017
Two abstracts featuring Vitatex technology will be presented as part of this year's ASCO conference in Chicago.
Vitatex Awarded NCI Contract for Circulating Tumor Cell (CTC) Capture and Preservation in Tubes
September 26, 2016
Vitatex announced today that it was awarded an SBIR Phase I/II Fast Track contract in September 2015 from the National Cancer Institute (NCI) for its Vita-Cap™ CTC Capture and Preservation tubes.
Gynecologic Oncology to Publish Vitatex Study on iCTCs in Ovarian Cancer
July 15, 2014
Vitatex Inc. announce that the journal Gynecologic Oncology has accepted for publication a key study by researchers from Vitatex and Stony Brook University entitled “Prognostic Analysis of Invasive Circulating Tumor Cells (iCTCs) in Epithelial Ovarian Cancer”. Vitatex iCTC Assay found to enable early detection of ovarian cancer.
AACR San Diego, California. April 5-9, 2014
March 27, 2014
Vitatex’s Scientific Founder Dr. Wen-Tien Chen will present a late breaking poster, Prognostic Analysis of Invasive Circulating Tumor Cells (iCTCs) to Monitor Epithelial Ovarian Cancer, which compares the use of iCTCs to CA125 in determining patients’ responses to surgery and chemotherapy.
Vitatex Licenses CAM CTC Technology to Noble Life Sciences for Metastasis Drug Development Services
December 05, 2013
Vitatex announced that it licensed its patented Cell Adhesion Matrix-Based (CAM) Enrichment technology for the isolation of viable metastasis-initiating invasive circulating tumor cells (iCTCs) to Noble Life Sciences (Gaithersburg, MD). Noble has obtained a $100,000 grant from Maryland to develop metastatic mouse models and ex vivo assays.